Exyte and Univercells Technologies are announcing a global partnership for optimized construction of modular standardized and flexible GMP manufacturing facilities for vaccines.
Read article "New partnership with Exyte for rapid deployment of vaccine production plants in the wake of the COVID-19 pandemic"Newsroom
Univercells Technologies, a global provider of next-generation bioprocess technologies, launches today. Under this new brand, the company will focus on the commercialization of the product portfolio and will explore new technology developments […]
Read article "Launch of Univercells Technologies for intensified, automated technologies"
The investment will be deployed in a newly created subsidiary of Univercells focused on accelerating the industrialization and commercialization of Univercells’ manufacturing technologies
Read article "€50M investment from KKR platform to accelerate the commercialization of technologies portfolio"
Bench-scale automated cell culture system featuring the scale-X single-use fixed-bed bioreactor offering 10 to 30 m² growth surface.
Read article "Introducing the single-use scale-X™ carbo bioreactor system"
Univercells and consortium partner Batavia Biosciences have been awarded a $4 million grant extension by the Bill & Melinda Gates Foundation to scale up their low-cost polio vaccine manufacturing technology.
Read article "Introducing the NevoLine™ sIPV platform"
Inauguration of new facility for the development and production of our technology solutions in Nivelles, Belgium
Read article "Inauguration of our new Equipment Design Center"
Univercells Receives $12 Million Grant to Develop Breakthrough Vaccine Manufacturing Platform
Read article "$12 million grant to develop breakthrough vaccine manufacturing platform"